Adaptimmune Therapeutics plc Total Liabilities

Latest as of June 2025: €201.59 Million EUR ≈ $235.68 Million USD

Adaptimmune Therapeutics plc total liabilities. Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has total liabilities worth €201.59 Million EUR (≈ $235.68 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 473A financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Adaptimmune Therapeutics plc (2016–2024)

Total liabilities of Adaptimmune Therapeutics plc from 2016 to 2024. This chart illustrates how Adaptimmune Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data.

Adaptimmune Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Adaptimmune Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
OS Therapies Incorporated NYSE MKT:OSTX	USA	$4.25 Million
MeVis Medical Solutions AG XETRA:M3V	Germany	€5.34 Million
Oceanpal Inc NASDAQ:OP	USA	$4.10 Million
Australian Vanadium Ltd AU:AVL	Australia	AU$13.62 Million
Arizona Gold & Silver Inc. V:AZS	Canada	CA$531.91K
Brunswick Exploration Inc V:BRW	Canada	CA$965.97K
AXIOS Sustainable Growth NYSE:AXAC	USA	$1.18 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Adaptimmune Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 473A total asset value.

Liquidity & Leverage Metrics

Adaptimmune Therapeutics plc Total Liabilities Ratios Explained

Adaptimmune Therapeutics plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.84	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.54	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Adaptimmune Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Adaptimmune Therapeutics plc (2016–2024)

The table below shows the annual total liabilities of Adaptimmune Therapeutics plc from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€234.11 Million ≈ $273.70 Million	-3.70%
2023-12-31	€243.10 Million ≈ $284.21 Million	-1.59%
2022-12-31	€247.04 Million ≈ $288.81 Million	-6.28%
2021-12-31	€263.58 Million ≈ $308.16 Million	+139.81%
2020-12-31	€109.92 Million ≈ $128.50 Million	+89.82%
2019-12-31	€57.91 Million ≈ $67.70 Million	+93.98%
2018-12-31	€29.85 Million ≈ $34.90 Million	-61.81%
2017-12-31	€78.16 Million ≈ $91.38 Million	+14.32%
2016-12-31	€68.37 Million ≈ $79.94 Million	--

About Adaptimmune Therapeutics plc

F:473A Germany

Market Cap

$50.20 Million

€42.94 Million EUR

Market Cap Rank

#22280 Global

#1968 in Germany

Share Price

€0.16

Change (1 day)

+0.00%

52-Week Range

€0.16 - €0.16

All Time High

€12.93